跨国药企加码中国市场 研发与投资项目相继落地

Group 1 - Recent policies and upgrades in the biopharmaceutical industry in China have led multiple multinational pharmaceutical companies to increase their investments in the country [1][2] - Pfizer has officially opened its third research and development center in China, aiming to accelerate the global synchronized development of innovative drugs to meet the growing demand from an aging population [1] - AstraZeneca announced a $2.5 billion investment to establish a global strategic R&D center in China, which will be its second in the country and sixth globally [1] Group 2 - AstraZeneca has also revealed several R&D collaborations with Chinese biotech firms, including a strategic investment of $105 million in Hengrui Medicine to co-develop next-generation multi-specific antibody therapies [2] - Other multinational companies like Eli Lilly and Takeda have also expressed intentions to strengthen their presence in the Chinese market, with Eli Lilly reporting a 9% growth in its business in China for 2024 [2] - The Chinese government's ongoing high-level opening-up policies and measures to simplify approval processes are expected to release policy dividends, providing ample growth opportunities for multinational pharmaceutical companies [2][3] Group 3 - The talent and R&D environment in China are highly attractive to multinational pharmaceutical companies, with the digital healthcare system and innovative industry clusters offering broader market space for development [3]